Welcome to our dedicated page for IceCure Medical news (Ticker: ICCM), a resource for investors and traders seeking the latest updates and insights on IceCure Medical stock.
IceCure Medical Ltd. develops and markets liquid-nitrogen-based cryoablation systems for minimally invasive tumor destruction. Its flagship ProSense® system is used for benign and cancerous lesions, with company updates centered on breast, kidney, bone and lung cancer indications and on markets where the device is cleared or approved, including the United States, Europe and Asia.
News about ICCM commonly covers ProSense commercialization, FDA-related breast cancer developments, post-market study activity, clinical evidence such as the ICESECRET kidney cancer study, medical-conference presentations, financial and operating results, and governance changes. The company’s updates also address physician training, reimbursement context and shareholder matters tied to its ordinary shares.
IceCure Medical (Nasdaq: ICCM), based in Caesarea, Israel, will release its financial and operational results for Q1 2024 on May 28, 2024, before the Nasdaq Stock Market opens. The company, which specializes in the ProSense® System, a cryoablation technology for tumor destruction, will hold a conference call at 11:00 a.m. EDT to discuss the results and other corporate updates. Interested parties can join via phone or live webcast.
IceCure Medical, developer of the ProSense® Cryoablation System, announced that CEO Eyal Shamir will present at the A.G.P / Alliance Global Partners' Virtual Healthcare Company Showcase on May 21, 2024. The presentation will cover key achievements, including the completion of the ICE3 breast cancer cryoablation trial, submission of results to the FDA, and a pending De Novo Classification Request for marketing clearance. Additionally, the company will highlight ProSense®'s growing global reach and its efficacy in women's health and interventional oncology. Shamir emphasized the significance of these developments for enhancing shareholder value and accelerating commercial goals in the U.S. market.
IceCure Medical (Nasdaq: ICCM) announced positive results from an independent study in Japan showing zero breast cancer local recurrence 5 years post-treatment with ProSense®. The study focused on safety, patient satisfaction, and cosmetic outcomes, with no local recurrence or distant metastasis reported. The strategic distribution partner in Japan, Terumo , is set to seek regulatory clearance for breast cancer treatment with ProSense®. Terumo holds exclusive distribution rights in Japan, with IceCure expected to receive $13.2 million in proceeds.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.